美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

美國抗疫概念

1,374.50

+9.860.72%

漲家數：15

跌家數：5

平家數：- -

市盈率：- -

高：1,380.29

開：1,364.76

低：1,358.78

收：1,364.65

資料載入中...

吉利德科學公司在美國就艾滋病藥物回扣問題達成和解，將支付 2.02 億美元

阿斯利康盤中異動下午盤股價大漲3.02%報72.05美元

吉利德科學公司就醫生回扣問題與美國達成 2.02 億美元和解協議

BUZZ-輝瑞公司季度利潤超預期，維持 2025 年預期；股價上漲

Co-Diagnostics, Inc.盤中異動急速拉昇5.07%報0.390美元

更正後的簡報-FDA 稱肝素鈉注射液，5000 [Usp'u]/1 毫升將因商業決定而停產 - 網站

美股異動丨輝瑞漲超3% Q1經調整每股盈利遠超預期擴大成本削減力度

輝瑞盤中異動早盤快速拉昇3.01%

輝瑞(PFE.N)漲近3%。

Aethlon Medical, Inc.盤中異動早盤股價大漲5.04%

Equillium, Inc.盤中異動股價大跌6.12%

新冠疫苗研發波折：Vaxart 獲轉機，行業仍陷困境

生物制品圈

Ibio, Inc.盤中異動快速上漲6.19%報1.12美元

Corvus Pharmaceuticals, Inc.盤中異動早盤股價大漲5.43%報3.69美元

美國食品和藥物管理局局長稱解僱不會妨礙該局的藥物審查目標日期

BUZZ-輝瑞公司季度利潤增長，維持 2025 年業績預期

輝瑞依靠削減成本抵消收入下降的影響

輝瑞季度銷售額不及預期，COVID 治療收入下降

阿斯利康一季報：中國區收入18億美元，ADC藥物驅動新增長

21世纪经济报道

阿斯利康盤前挫2.65% 將終止針對其前列腺癌治療藥物三期臨牀試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1374.5028,"timestamp":1746043199999,"preClose":1364.6454,"halted":0,"volume":104804668,"delay":0,"changeRate":0.007223,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":9.857422,"latestTime":"04-30 16:00:00 EDT","open":1364.7573,"high":1380.285,"low":1358.7754,"amount":5368600814.512648,"amplitude":0.015762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1746057600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.640146,"peRate":22.008402,"turnoverRate":0.006758,"increases":15,"decrements":5,"flats":0,"marketCap":1135599575121,"floatMarketCap":1115674225455},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1380.285,"amplitude":0.015762,"preClose":1364.6454,"low":1358.7754,"pbRate":"3.640146","latestPrice":1374.5028,"volume":104804668,"delay":0,"open":1364.7573,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1344.1606,"twentyDayClose":1377.6108,"sixtyDayClose":1350.7439,"secType":"PLATE","market":"US","turnoverRate":0.006758,"peRate":22.008402,"marketCap":1135599575121,"floatMarketCap":1115674225455,"timestamp":1746043199999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":15,"down":5,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531760523","title":"吉利德科學公司在美國就艾滋病藥物回扣問題達成和解，將支付 2.02 億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531760523","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531760523?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 02:31","pubTimestamp":1745951487,"startTime":"0","endTime":"0","summary":"更新版 1-吉利德科学公司在美国就艾滋病药物回扣问题达成和解，将支付 2.02 亿美元改写第一段；添加吉利德公司和美国律师的评论、指控、举报人详情、财务影响、署名Jonathan Stempel. 路透纽约4月29日 - 吉利德科学公司同意支付2.02亿美元，以了结一起举报人诉讼，该诉讼指控吉利德向同意开具其艾滋病药物处方的医生支付回扣，涉嫌民事欺诈。2024 年，吉利德的艾滋病药物销售总额达 196.1 亿美元，同比增长 8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R728V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU1571399168.USD","LU2087621335.USD","BK4585","LU1585245621.USD","BK4578","IE00B19Z3581.USD","LU0289739699.SGD","IE0002270589.USD","LU0058720904.USD","LU0234570918.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","GILD","BK4532","LU2089984988.USD","LU0109394709.USD","LU0889565916.HKD","BK4139","IE00B7SZLL34.SGD","BK4583","LU1430594728.SGD","LU1066051498.USD","BK4568","LU1066053197.SGD","LU1839511570.USD","BK4588","LU0320765992.SGD","LU2468319806.SGD","IE00BKVL7J92.USD","BK4550","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2531762855","title":"阿斯利康盤中異動 下午盤股價大漲3.02%報72.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531762855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531762855?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 01:40","pubTimestamp":1745948447,"startTime":"0","endTime":"0","summary":"北京时间2025年04月30日01时40分，阿斯利康股票出现波动，股价大幅拉升3.02%。截至发稿，该股报72.05美元/股，成交量543.799万股，换手率0.18%，振幅3.30%。阿斯利康股票所在的制药行业中，整体涨幅为1.44%。该信息摘要如下：阿斯利康公布的2025年第一季度利润超出预期，并重申其全年业绩指引。财报显示，阿斯利康一季度总营收135.9亿美元，不及市场预期；核心每股收益为 2.49 美元，同比增长21%，超过分析师预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430014047a6cda7e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430014047a6cda7e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2236285917.USD","LU0320765992.SGD","LU1829250122.USD","BK4007","BK4585","AZN","LU0109394709.USD","LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","BK4588","BK4568","LU2456880835.USD"],"gpt_icon":0},{"id":"2531764411","title":"吉利德科學公司就醫生回扣問題與美國達成 2.02 億美元和解協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2531764411","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531764411?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 01:39","pubTimestamp":1745948380,"startTime":"0","endTime":"0","summary":"吉利德科学公司就医生回扣问题与美国达成 2.02 亿美元和解协议路透纽约4月29日 - 美国曼哈顿检察官办公室周二表示，吉利德科学公司GILD.O已达成一项2.02亿美元的和解协议，以解决一起指控该公司向同意处方其艾滋病药物的医生支付回扣的民事欺诈诉讼。该和解协议解决了吉利德公司向参加吉利德公司演讲活动的医生支付酬金、餐费和差旅费，以诱使他们开具几种艾滋病药物处方的指控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R7264:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU1430594728.SGD","IE00B19Z3581.USD","BK4532","LU1066051498.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","BK4566","BK4550","IE0002270589.USD","LU0058720904.USD","LU2468319806.SGD","BK4585","BK4139","BK4568","LU0109394709.USD","LU1839511570.USD","LU2087621335.USD","LU1585245621.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU2089984988.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","BK4578","LU1066053197.SGD","GILD","LU0234570918.USD","BK4583","BK4588","IE00BSNM7G36.USD","LU0320765992.SGD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2531766955","title":"BUZZ-輝瑞公司季度利潤超預期，維持 2025 年預期；股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766955","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766955?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 00:41","pubTimestamp":1745944911,"startTime":"0","endTime":"0","summary":"** 由于 Paxlovid COVID-19 疗法销售额下降，PFE 第一季度营收不及预期，但该公司仍 坚持610 亿至 640 亿美元的财年营收预期。** 包括本交易日的走势在内，PFE 在今年已累计下跌约10(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R723X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","PFE","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","BK4588","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","LU0306806265.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2531577377","title":"Co-Diagnostics, Inc.盤中異動 急速拉昇5.07%報0.390美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531577377","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531577377?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 23:27","pubTimestamp":1745940471,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日23时27分，Co-Diagnostics, Inc.股票出现波动，股价快速上涨5.07%。Co-Diagnostics, Inc.股票所在的医疗器械行业中，整体涨幅为0.10%。Co-Diagnostics, Inc.公司简介：Co-Diagnostics Inc是一家分子诊断公司。该公司还利用其专有技术为其 Co-Dx PCR 平台设计特定测试，并定位用于传染病以外应用的遗传标记。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429232751974a5c7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429232751974a5c7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","CODX","BK4568"],"gpt_icon":0},{"id":"2531752002","title":"更正後的簡報-FDA 稱肝素鈉注射液，5000 [Usp'u]/1 毫升將因商業決定而停產 - 網站","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752002","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752002?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 23:24","pubTimestamp":1745940292,"startTime":"0","endTime":"0","summary":"更正后的简报-FDA 称肝素钠注射液，5000 [Usp'u]/1 毫升将因商业决定而停产 - 网站来源更正为美国食品及药物管理局，而非辉瑞公司路透4月29日 - 美国食品和药物管理局：FDA：肝素钠，注射剂，5000[USP'U]/1 毫升，因商业决定将停产 - 网站(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R71YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","BK4533","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","BK4550","LU0985481810.HKD","LU1883839398.USD","IE000M9KFDE8.USD","LU0456855351.SGD","SG9999011175.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU1066051498.USD","LU0306806265.USD","SG9999002232.USD","LU1023059063.AUD","LU1057294990.SGD","BK4534","BK4592","LU0225771236.USD","SGXZ57979304.SGD","SG9999003800.SGD","IE00BLSP4239.USD","BK4599","BK4581","IE00BBT3K403.USD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","LU1894683348.USD","LU0306807586.USD","LU0321505868.SGD","BK4007","LU0321505439.SGD","SG9999013999.USD","SG9999002224.SGD","BK4568","IE0002270589.USD","LU0868494617.USD","LU0289739699.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"2531757594","title":"美股異動丨輝瑞漲超3% Q1經調整每股盈利遠超預期 擴大成本削減力度","url":"https://stock-news.laohu8.com/highlight/detail?id=2531757594","media":"格隆汇APP","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531757594?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 23:11","pubTimestamp":1745939460,"startTime":"0","endTime":"0","summary":"格隆汇4月29日｜辉瑞(PFE.US)涨超3%，报23.755美元。消息面上，辉瑞周二公布，在加大成本削减力度下，首季净利润同比跌约5%至29.7亿美元，经调整每股盈利92美仙，远高于市场预期的66美仙；营收同比跌8%至137.2亿美元，反映其抗病毒药物Paxlovid的收入减少。公司预计，通过两项成本削减措施，到2027年底将节省约77亿美元。公司维持对2025年全年财报的预期，预计销售额为610亿至640亿美元，惟补充该指引目前不包括与未来关税和贸易政策变化相关的任何潜在影响。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-04-29/doc-ineuwcvn0721829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SGXZ57979304.SGD","IE00BLSP4239.USD","LU0289739699.SGD","IE00B19Z3581.USD","BK4533","BK4599","LU0868494617.USD","LU1066051498.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","LU1894683264.USD","LU0321505868.SGD","LU1894683348.USD","LU0225284248.USD","LU1883839398.USD","SG9999002232.USD","BK4550","IE0002270589.USD","LU0058720904.USD","PFE","LU1057294990.SGD","LU0122379950.USD","IE00BBT3K403.USD","SG9999001176.USD","BK4585","BK4568","IE000M9KFDE8.USD","SG9999003800.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999002224.SGD","SG9999013999.USD","LU0985481810.HKD","LU0170899867.USD","LU1066053197.SGD","SG9999001176.SGD","LU0321505439.SGD","LU0234572021.USD","BK4592","LU1023059063.AUD","BK4581","LU0306806265.USD","LU0225771236.USD","BK4588","BK4534","BK4007","LU0306807586.USD"],"gpt_icon":0},{"id":"2531545567","title":"輝瑞盤中異動 早盤快速拉昇3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531545567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531545567?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 22:50","pubTimestamp":1745938226,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日22时50分，辉瑞股票出现异动，股价急速拉升3.01%。截至发稿，该股报23.74美元/股，成交量3271.13万股，换手率0.58%，振幅5.53%。辉瑞股票所在的制药行业中，整体涨幅为1.01%。辉瑞公司简介：辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。与其他受贸易政策变化影响的公司不同，辉瑞并未调整其业绩预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429225026aa2c7e45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429225026aa2c7e45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","BK4585","IE000M9KFDE8.USD","BK4568","SG9999001176.SGD","SG9999001176.USD","IE00BLSP4239.USD","LU0321505439.SGD","PFE","LU0321505868.SGD","LU1894683264.USD","SG9999013999.USD","LU0306807586.USD","LU0170899867.USD","BK4588","BK4581","IE00BLSP4452.SGD","LU1023059063.AUD","BK4534","LU0225284248.USD","SG9999002232.USD","LU0868494617.USD","BK4007","LU1066053197.SGD","SG9999002224.SGD","IE0002270589.USD","LU1883839398.USD","LU0289739699.SGD","LU0306806265.USD","SG9999003800.SGD","LU1066051498.USD","LU0985481810.HKD","SGXZ57979304.SGD","IE00BBT3K403.USD","BK4599","IE00B19Z3581.USD","LU0225771236.USD","BK4592","LU0058720904.USD","LU0122379950.USD","LU1894683348.USD","SG9999011175.SGD","LU0234572021.USD","LU0456855351.SGD","LU1057294990.SGD","BK4533","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2531751539","title":"輝瑞(PFE.N)漲近3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751539","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751539?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 22:48","pubTimestamp":1745938133,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4568","BK4588","SG9999013999.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999001176.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4599","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","IE00B19Z3581.USD","SG9999002232.USD","BK4007","LU0868494617.USD","LU0170899867.USD","LU0225284248.USD","LU0234572021.USD","IE0002270589.USD","LU0456855351.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","BK4533","SG9999003800.SGD","LU1894683348.USD","LU0122379950.USD","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4550","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","BK4581","LU0321505868.SGD","BK4592","BK4585","LU1023059063.AUD","SGXZ57979304.SGD","LU0225771236.USD"],"gpt_icon":0},{"id":"2531755299","title":"Aethlon Medical, Inc.盤中異動 早盤股價大漲5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531755299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531755299?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 22:07","pubTimestamp":1745935664,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日22时07分，Aethlon Medical, Inc.股票出现异动，股价急速拉升5.04%。截至发稿，该股报0.417美元/股，成交量2.6382万股，换手率0.16%，振幅3.78%。Aethlon Medical, Inc.股票所在的医疗器械行业中，整体涨幅为0.45%。其相关个股中，Inspiremd Inc.、Autonomix Medical, Inc.、飞天兆业涨幅较大，Tivic Health Systems, Inc.、Invo Fertility, Inc.、Autonomix Medical, Inc.较为活跃，换手率分别为29.14%、20.66%、12.27%，振幅较大的相关个股有Tivic Health Systems, Inc.、Autonomix Medical, Inc.、Dih Holding Us, Inc.，振幅分别为18.01%、17.95%、15.10%。Aethlon Medical, Inc.公司简介：Aethlon Medical Inc 是一家医疗技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429220744a46c4925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429220744a46c4925&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","TIVC","BK4583","AEMD","BK4082"],"gpt_icon":0},{"id":"2531275347","title":"Equillium, Inc.盤中異動 股價大跌6.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531275347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531275347?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:57","pubTimestamp":1745935059,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时57分，Equillium, Inc.股票出现异动，股价快速下跌6.12%。Equillium, Inc.股票所在的生物技术行业中，整体跌幅为1.40%。Equillium, Inc.公司简介：Equillium Inc是一家临床阶段的生物技术公司，致力于开发新的治疗方法，以治疗严重的自身免疫性和炎症性疾病，或免疫炎症性疾病，具有高度未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429215741974a4142&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429215741974a4142&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2531134867","title":"新冠疫苗研發波折：Vaxart 獲轉機，行業仍陷困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2531134867","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531134867?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:56","pubTimestamp":1745935014,"startTime":"0","endTime":"0","summary":"近日，疫苗研发领域动态频出，Vaxart 公司迎来好消息，其新冠疫苗研究的暂停令被解除，研发进程得以重启。此前，HHS 在 2 月冻结了 Vaxart 的试验，这一举措使得该公司与政府签订的价值数十亿美元的口服新冠疫苗研发合同陷入僵局。其他公司受阻，研发之路艰难尽管 Vaxart 迎来转机，但其他新冠疫苗研发企业却仍在困境中挣扎。Vaxart 公司新冠疫苗研究的恢复为其带来了希望，但新冠疫苗研发行业整体仍面临监管、舆论等多方面的压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430052357a46cac01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430052357a46cac01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VXRT","BK4009","HHS","BK4568","BK4139"],"gpt_icon":0},{"id":"2531312730","title":"Ibio, Inc.盤中異動 快速上漲6.19%報1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531312730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531312730?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:33","pubTimestamp":1745933617,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时33分，Ibio, Inc.股票出现异动，股价急速上涨6.19%。截至发稿，该股报1.12美元/股，成交量12.66万股，换手率1.26%，振幅3.81%。Ibio, Inc.股票所在的生物技术行业中，整体跌幅为1.92%。Ibio, Inc.公司简介：iBio公司是一家临床前阶段生物技术公司，利用人工智能的力量开发精准抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213337aa2c7e03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213337aa2c7e03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","IBIO","BK4139"],"gpt_icon":0},{"id":"2531410753","title":"Corvus Pharmaceuticals, Inc.盤中異動 早盤股價大漲5.43%報3.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531410753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531410753?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933547,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时32分，Corvus Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.43%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.55%。其相关个股中，Cyclacel Pharmaceuticals, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 涨幅较大，Zyversa Therapeutics, Inc.、Onconetix, Inc.、Galmed Pharmaceuticals Ltd.较为活跃，换手率分别为132.52%、39.26%、11.58%，振幅较大的相关个股有Cyclacel Pharmaceuticals, Inc.、Ernexa Therapeutics Inc.、Promis Neurosciences Inc.，振幅分别为12.12%、12.10%、9.62%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213228aa2c7e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213228aa2c7e00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0},{"id":"2531773684","title":"美國食品和藥物管理局局長稱解僱不會妨礙該局的藥物審查目標日期","url":"https://stock-news.laohu8.com/highlight/detail?id=2531773684","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531773684?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 20:42","pubTimestamp":1745930559,"startTime":"0","endTime":"0","summary":"美国食品和药物管理局局长表示，尽管特朗普政府大规模解雇了该机构的人员，但美国食品和药物管理局仍将实现完成新药审查的目标。路透 4 月初报道称，该机构大规模解雇 了 对新药审评 至关重要的   员工，包括所有负责管理新产品申请等记录的 员工。马卡里还表示，他可以在该机构独立做出决定。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R71CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4585","BK4139","BK4568","BK4588"],"gpt_icon":1},{"id":"2531641786","title":"BUZZ-輝瑞公司季度利潤增長，維持 2025 年業績預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2531641786","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531641786?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924560,"startTime":"0","endTime":"0","summary":"** 虽然第一季度营收不及预期，但仍坚持610-640亿美元的财年营收预期 ** 同时，维持 2.80 美元至 3.00 美元的财年每股收益预期。** 截至上次收盘，PFE 年累计下跌约 13 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU0321505868.SGD","LU1023059063.AUD","PFE","BK4585","BK4534","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","BK4581","LU0868494617.USD","LU0306807586.USD","SG9999011175.SGD","BK4568","LU1066051498.USD","LU0456855351.SGD","BK4533","SG9999003800.SGD","LU0321505439.SGD","BK4599","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","LU0306806265.USD","BK4592","SG9999013999.USD","IE00BBT3K403.USD","SG9999001176.SGD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","LU0234572021.USD","BK4588","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2531785467","title":"輝瑞依靠削減成本抵消收入下降的影響","url":"https://stock-news.laohu8.com/highlight/detail?id=2531785467","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531785467?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924425,"startTime":"0","endTime":"0","summary":"更新版 6-辉瑞依靠削减成本抵消收入下降的影响辉瑞公布喜忧参半的第一季度业绩，维持全年预期 COVID 疫苗销售好于预期，而抗病毒治疗销售下降预计到 2027 年底可节省 77 亿美元成本 第 8-9 段增加了首席执行官访谈中关于关税的评论Bhanvi Satija/Michael Erman. 路透4月29日 - 辉瑞PFE.N周二表示，公司将通过削减生产和研究业务的成本再节约17亿美元，尽管由于其COVID-19治疗药物Paxlovid的销售下降导致第一季度收入减少，但辉瑞仍强调了其运营效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","BK4599","BK4534","BK4581","BK4592","LU0234572021.USD","LU1057294990.SGD","BK4585","PFE","BK4533","IE00BLSP4239.USD","SG9999002232.USD","LU1883839398.USD","SG9999013999.USD","LU1066051498.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0306807586.USD","LU0058720904.USD","LU0225284248.USD","LU0321505868.SGD","SG9999011175.SGD","LU0225771236.USD","IE0002270589.USD","LU1894683264.USD","IE00BLSP4452.SGD","BK4568","BK4007","IE00B19Z3581.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU0306806265.USD","LU0122379950.USD","LU1066053197.SGD","SG9999003800.SGD","SG9999001176.SGD","LU0289739699.SGD","LU0868494617.USD","LU1894683348.USD","SG9999001176.USD","SGXZ57979304.SGD","LU0321505439.SGD","SG9999002224.SGD","LU0985481810.HKD","BK4588","LU0170899867.USD","BK4550"],"gpt_icon":1},{"id":"2531378394","title":"輝瑞季度銷售額不及預期，COVID 治療收入下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2531378394","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531378394?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 18:49","pubTimestamp":1745923795,"startTime":"0","endTime":"0","summary":"辉瑞季度销售额不及预期，COVID 治疗收入下降路透4月29日 - 美国制药商辉瑞PFE.N周二公布的第一季度收入低于华尔街预期，受其COVID抗病毒治疗药物Paxlovid销售下滑的影响。 LSEG的数据显示，该公司第一季度总营收为137.0亿美元，而分析师预期为139.1亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R70Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","BK4588","LU0868494617.USD","LU0306806265.USD","BK4581","BK4568","LU1894683264.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4599","LU0321505868.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU0225284248.USD","IE00BLSP4452.SGD","SG9999002224.SGD","BK4533","LU0306807586.USD","BK4585","IE00BLSP4239.USD","LU1883839398.USD","LU1057294990.SGD","LU0234572021.USD","LU0985481810.HKD","LU1066053197.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999011175.SGD","IE000M9KFDE8.USD","IE0002270589.USD","SG9999013999.USD","BK4534","SG9999002232.USD","LU0321505439.SGD","BK4007","LU0225771236.USD","PFE","SG9999001176.USD","LU0456855351.SGD","SG9999001176.SGD","BK4550","SGXZ57979304.SGD","LU1894683348.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2531022292","title":"阿斯利康一季報：中國區收入18億美元，ADC藥物驅動新增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2531022292","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531022292?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 17:56","pubTimestamp":1745920574,"startTime":"0","endTime":"0","summary":"根据财报，今年一季度阿斯利康在美国收入 56.46 亿美元，同比增长10%，占总营收的 42%；中国区收入 18.05 亿美元，同比增长5%，占总营收的 13%。而ADC 药物德曲妥珠单抗增长势头强劲，今年第一季度的销售额为10.86 亿美元。阿斯利康的财报印证了其在“专利悬崖”前的未雨绸缪：通过ADC药物打开新增量，以多元化管线平衡风险，并借力中国市场实现全球化纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291758349749f61d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291758349749f61d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","ADC","BK4231","LU1829250122.USD","AZN","LU2236285917.USD","BK4585","LU2462157665.USD","BK4588","LU0320765992.SGD","LU2456880835.USD","LU0889565916.HKD","BK4080","LU0109394709.USD","LU2417539215.USD","BK4007"],"gpt_icon":0},{"id":"2531270717","title":"阿斯利康盤前挫2.65% 將終止針對其前列腺癌治療藥物三期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2531270717","media":"金吾资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531270717?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 17:00","pubTimestamp":1745917203,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)盘前股价下挫，暂跌2.65%，报68.08美元。消息面上，公司将终止针对其前列腺癌治疗药物Truqap的CAPITello-280三期临床试验，原因是该试验不太可能达到双重主要终点。公司周二称，这一决定是在审查了独立数据监测委员会建议的中期分析数据后作出的。该公司表示，与使用多西他赛和雄激素剥夺疗法（ADT）加安慰剂的对照组相比，Truqap联合多西他赛和ADT的治疗方案，在转移性去势抵抗性前列腺癌患者中，可能无法达到影像学无进展生存期和总生存期的主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291701509749e2b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291701509749e2b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU1829250122.USD","LU2462157665.USD","BK4588","LU2236285917.USD","LU0889565916.HKD","LU0320765992.SGD","LU2417539215.USD","AZN","BK4007","LU2456880835.USD","LU0109394709.USD","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":189,"code":"91000000","status":"200"}]}}